Grants
Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity | Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Functional and Structural Diversity in Hypoglossal Motoneurons | Grant | $1,705,570.00 | Research | Ralph Fregosi | Physiology | National Institute on Deafness and Other Communication Disorders | 11/2022 |
| Dissecting innate drivers of durable immunity | Grant | $587,555.00 | Research | Deepta Bhattacharya | Immunobiology | Bill and Melinda Gates Foundation | 11/2022 |
| Determining Sex Hormone Effects on Symptom Exacerbation And Abatement Across The Complete Menstrual Cycle | Grant | $5,000.00 | Research | Jennifer Andrews | Pediatrics | Ehlers-Danlos Society | 11/2022 |
| Defining and Ablating Immunological Barriers to Hematopoietic Cell Transplants | Contract | $406,250.00 | Research | Michael Kuhns | Immunobiology | Clade Therapeutics | 11/2022 |
| Barriers to Treatment and Testing for Helicobacter pylori among Navajo- Navajo Healthy Stomach Project | Grant | $11,862.00 | Research | Robin Harris | Epidemiology and Biostatistics | John Wayne Cancer Foundation | 11/2022 |
| African Ancestry Genomic Psychiatry Cohort | Grant | $55,105.00 | Research | Ayman Fanous | COM Phx Psychiatry | Rutgers, The State University of New Jersey | 11/2022 |
| #4Corners4Health: A Social Media Cancer Prevention Program for Rural Emerging Adults | Grant | $781,177.00 | Research | Cynthia Thomson | Health Promotion Sciences | Klein Buendel, Incorporated | 11/2022 |
| Rural Transfer Line | Contract | $1,980,000.00 | Other Sponsored Activity | Steven Dudley | COM Phx Ctr Tox&Pharm Ed&Res | Arizona Department of Health Services | 11/2022 |
| Raising Special Kids External Evaluation Project | Contract | $60,000.00 | Other Sponsored Activity | Wendy Parent-Johnson | Family and Community Medicine | Raising Special Kids | 11/2022 |
| Mobile Health Program | Grant | $10,000.00 | Other Sponsored Activity | Ronald Sorensen | Family and Community Medicine | American Academy of Family Physicians Foundation | 11/2022 |
| Evaluating the Impact of Arizona's Health Start Program on Maternal Health Outcomes | Grant | $38,174.00 | Other Sponsored Activity | Patrick Wightman | UAHS Research | Northern Arizona University | 11/2022 |
| Arizona Poison and Drug Information System (APDIS) Monkeypox ISA | Contract | $635,857.54 | Other Sponsored Activity | Steven Dudley | COM Phx Ctr Tox&Pharm Ed&Res | Arizona Department of Health Services | 11/2022 |
| Arizona Poison and Drug Information System (APDIS) Monkeypox | Contract | $635,857.54 | Other Sponsored Activity | Steven Dudley | COM Phx Ctr Tox&Pharm Ed&Res | Arizona Department of Health Services | 11/2022 |
| Treatment of Persistent Atrial Fibrillation with the Sphere-9 Mapping and Ablation Catheter and the Affera Mapping and Ablation System | Contract | $344,863.60 | Clinical Trial | Roderick Tung | COM Phx Internal Medicine | Affera, Inc. | 11/2022 |
| The Role of Milk Fat Globule Membrane and 2'-Fucosyllactose in the Infant Gut Microbiota | Contract | $368,171.12 | Clinical Trial | Fayez Ghishan | Pediatrics | Mead Johnson | 11/2022 |
| Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II (COSIRA-II) | Contract | $175,514.00 | Clinical Trial | Michel Corban | Sarver Heart Center | Neovasc Inc. | 11/2022 |
| Developing a Trial-Ready Cohort of Parkinson Disease Patients | Contract | $122,136.00 | Clinical Trial | Scott Sherman | Neurology | Aspen Neuroscience | 11/2022 |
| Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients with Advanced Dedifferentiated Liposarcoma | Contract | $175,639.80 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Boehringer Ingelheim Pharmaceuticals, Inc | 11/2022 |
| Abbott DBS Post-Market Study of Outcomes for Indications over Time | Contract | $432,142.00 | Clinical Trial | Hong Lei | Neurology | Abbott Laboratories | 11/2022 |
| A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | Contract | $288,141.12 | Clinical Trial | Rachna Shroff | Cancer Center Division | Surface Oncology Inc. | 11/2022 |
| A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small | Contract | $274,708.68 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Loxo Oncology, Inc. | 11/2022 |
| A Phase 2, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects with Pulmonary Arterial | Contract | $113,987.00 | Clinical Trial | Franz Rischard | Medicine | Respira Therapeutics, Inc. | 11/2022 |
| A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Unresectable, Recurrent or Metastat | Contract | $142,725.32 | Clinical Trial | Jennifer Segar | Cancer Center Division | Riboscience LLC | 11/2022 |
| 1/2 Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | Grant | $172,350.00 | Clinical Trial | Mary Gaspers | Pediatrics | University of Michigan | 11/2022 |
| Human Endothelial Cell Heterogeneity and Activation in Atherosclerosis | Fellowship | $41,503.00 | Research Training | Maria Adelus | Cellular & Molecular Medicine | National Heart, Lung, and Blood Institute | 10/2022 |